<DOC>
	<DOC>NCT00541229</DOC>
	<brief_summary>A study to assess the safety and efficacy of sitagliptin 100mg compared to sitagliptin 200mg in patients with type 2 diabetes.</brief_summary>
	<brief_title>Sitagliptin Dose Comparison Study in Patients With Type 2 Diabetes (MK-0431-077)(COMPLETED)</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<mesh_term>Sitagliptin Phosphate</mesh_term>
	<criteria>Patient has Type 2 Diabetes Patient is between the ages of 3065 years Patient is not on an antihyperglycemic agent (AHA) (glycosylated hemoglobin [A1C] 710% ), or is on oral single AHA or lowdose combination therapy (A1C 6.59.5%). Patient has Type 1 Diabetes Patient has been treated with sitagliptin, vildagliptin, or other similar drugs or has been treated with exenatide in the past 3 months Patient has taken insulin within the past 3 months</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>February 2015</verification_date>
</DOC>